Sees FY25 non-GAAP gross margin of 76%-78%, FY25 non-GAAP R&D expense of $90M-$105M, and FY25 non-GAAP SG&A expense of $290M-$320M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX: